These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1026 related articles for article (PubMed ID: 22382007)

  • 1. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumorigenic and prognostic significance of RASSF1A expression in low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer.
    Ha YS; Jeong P; Kim JS; Kwon WA; Kim IY; Yun SJ; Kim GY; Choi YH; Moon SK; Kim WJ
    Urology; 2012 Jun; 79(6):1411.e1-6. PubMed ID: 22446336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
    Yun SJ; Jo SW; Ha YS; Lee OJ; Kim WT; Kim YJ; Lee SC; Kim WJ
    Urol Oncol; 2012; 30(6):893-9. PubMed ID: 21396842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping.
    Kim EJ; Yan C; Ha YS; Jeong P; Yi Kim I; Moon SK; Choi YH; Kim WJ
    Urol Oncol; 2012 Sep; 30(5):673-9. PubMed ID: 20884250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
    Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
    Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
    Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
    Catto JW; Azzouzi AR; Rehman I; Feeley KM; Cross SS; Amira N; Fromont G; Sibony M; Cussenot O; Meuth M; Hamdy FC
    J Clin Oncol; 2005 May; 23(13):2903-10. PubMed ID: 15753461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation identifies progression risk in bladder cancer.
    Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
    Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
    Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
    Lee SM; Lee WK; Kim DS; Park JY
    Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.